Home » Authors » James Etheridge

Articles by James Etheridge

Aptanomics Raises EUR7M For Peptide Aptamer-Based Platform

Nov. 6, 2002

By James Etheridge

Avidis Closing EUR1.7M Round To Develop Peptides Technology

Nov. 6, 2002

By James Etheridge

Aptanomics Raises EUR7M For Peptide Aptamer-Based Platform

Nov. 6, 2002

By James Etheridge

Genome Express Unveils New Gene Discovery Technology

Oct. 30, 2002

By James Etheridge

IDM Enters Research Agreement With Nemod On Immunotherapies

Oct. 30, 2002

By James Etheridge

Genset Delists From Nasdaq, Closes Paris Headquarters

Oct. 30, 2002

By James Etheridge

ExonHit Initiates Clinical Trial Of Lead Compound For ALS

Oct. 30, 2002

By James Etheridge

ExonHit Initiates Clinical Trial Of Lead Compound For ALS

Oct. 30, 2002

By James Etheridge

Genome Express Unveils New Gene Discovery Technology

Oct. 30, 2002

By James Etheridge

Genset Delists From Nasdaq, Closes Paris Headquarters

Oct. 30, 2002

By James Etheridge

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 2, 2026.
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...